These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9194115)

  • 1. Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.
    Spector SA; Blanchard S; Wara DW; Oleske JM; McIntosh K; Hodes D; Dankner WM; Salgo M; McNamara J
    Pediatr Infect Dis J; 1997 Jun; 16(6):623-6. PubMed ID: 9194115
    [No Abstract]   [Full Text] [Related]  

  • 2. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
    Fischl MA; Olson RM; Follansbee SE; Lalezari JP; Henry DH; Frame PT; Remick SC; Salgo MP; Lin AH; Nauss-Karol C; Lieberman J; Soo W
    Ann Intern Med; 1993 May; 118(10):762-9. PubMed ID: 8097082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
    Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
    J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
    Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
    Fiscus SA; Hughes MD; Lathey JL; Pi T; Jackson B; Rasheed S; Elbeik T; Reichman R; Japour A; Byington R; Scott W; Griffith BP; Katzenstein DA; Hammer SM
    J Infect Dis; 1998 Mar; 177(3):625-33. PubMed ID: 9498441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
    Vanhove GF; Gries JM; Verotta D; Sheiner LB; Coombs R; Collier AC; Blaschke TF
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2433-8. PubMed ID: 9371346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine.
    Viani RM; Smith IL; Spector SA
    J Infect Dis; 1998 Mar; 177(3):565-70. PubMed ID: 9498433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus infection in children.
    Hoernle EH; Reid TE
    Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV therapy advances. Pediatric antiretroviral choices.
    Spector SA
    AIDS; 1994 Sep; 8 Suppl 3():S15-8. PubMed ID: 7840911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Delta trial.
    Zaretsky MD
    Lancet; 1997 Feb; 349(9048):358-9. PubMed ID: 9024402
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
    J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.